Creating a policy environment that supports innovation
A favourable policy environment is critical to the success of health innovation—setting the context in which a research-intensive organization will flourish or fail, make the decision to invest, or expect the value of its innovations to be recognized and rewarded. Sound policy strategy must be rooted in objectivity: objectivity that rises above narrow commercial interests; objectivity that avoids spin and considers evidence contrary to desired messaging; and objectivity that helps policymakers make the best decisions on behalf of their public constituencies.
Shift Health supports policy teams in creating evidence-based strategies and communication materials to navigate, inform and influence the complex web of policy and related stakeholders. Through the pursuit and presentation of impartial evidence, we help our clients develop ironclad advocacy positions that serve long-term interests. We are forthright when the data do not support a preferred position; and we bring a discerning eye to create responsible policy strategies that build credibility, enable policy partnership, and serve both societal and corporate interests.
Policy Landscape Assessment – Stakeholder Mapping – Policy Narrative – Stakeholder Engagement
A top-5 pharmaceutical company needed to prepare decision-makers for the patient and health system impact of disease-modifying therapies and diagnostic biomarkers for Alzheimer’s disease.
A large biotech firm needed support in developing an evidence-based policy narrative in preparation for the launch of a CAR T-cell therapy for a rare form of cancer.
Creating a Global Policy Strategy to Support the Launch of an Innovative Influenza Antiviral for a Top-5 Pharma Company
The global headquarters of a top-5 pharmaceutical company needed to develop a global policy strategy to support the launch of a new treatment for influenza.
A global biopharmaceutical company recognized the need to work in partnership with healthcare systems in order to realize the vital, long-term potential of a personalized approach to healthcare.
A multinational pharmaceutical company sought support to engage with haemophilia A individuals and caregivers to gather firsthand perspectives on the impact of current and value of future therapies.